Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.00
Bid: 68.00
Ask: 70.00
Change: 0.00 (0.00%)
Spread: 2.00 (2.941%)
Open: 69.00
High: 69.00
Low: 69.00
Prev. Close: 69.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Nov 2015 07:00

RNS Number : 2698F
NetScientific PLC
11 November 2015
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

NetScientific plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Woodford Investment Management LLP ("Woodford")

4. Full name of shareholder(s)  (if different from 3.):iv

Clients of Woodford

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

09.11.15

6. Date on which issuer notified:

10.11.15

7. Threshold(s) that is/are crossed orreached: vi, vii

 21% - 45% (inclusive)

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B9F4MT28

10,545,125

10,545,125

23,045,125

23,045,125

45.2%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

23,045,125

45.2%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Woodford, as Investment Manager

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Jon Webb

15. Contact telephone number:

01865 809023

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLGGGAPGUPAGBU
Date   Source Headline
24th Aug 202011:28 amRNSResult of General Meeting
21st Aug 20201:23 pmRNSHolding(s) in Company
21st Aug 202011:47 amRNSIssue of Equity
14th Aug 202010:48 amRNSPDS Announces Closing of $19m Offering
12th Aug 202012:28 pmRNSSofant secures £2.3m funding led by EMV Capital
12th Aug 20207:00 amRNSPDS Announces Pricing of $16.5m Common Stock Offer
11th Aug 202012:27 pmRNSPDS Announces Proposed Offering of Common Stock
7th Aug 20209:32 amRNSPosting of shareholder circular
6th Aug 20202:00 pmRNSHolding(s) in Company
5th Aug 202010:32 amRNSResult of Placing
5th Aug 20208:30 amRNSProposed acquisition and placing
4th Aug 202011:05 amRNSSecond Price Monitoring Extn
4th Aug 202011:00 amRNSPrice Monitoring Extension
27th Jul 20203:06 pmRNSPDS Announces Preclinical Data for PDS0203
14th Jul 20204:20 pmRNSPDS collaborator awarded grant for Versamune
29th Jun 20207:00 amRNSG–Tech Medical completes $6.7m Series A financing
25th Jun 20204:41 pmRNSSecond Price Monitoring Extn
25th Jun 20204:35 pmRNSPrice Monitoring Extension
24th Jun 20205:58 pmRNSHolding(s) in Company
24th Jun 20205:54 pmRNSHolding(s) in Company
24th Jun 20204:09 pmRNSResult of AGM
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
18th Jun 202011:05 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
18th Jun 20209:05 amRNSSecond Price Monitoring Extn
18th Jun 20209:00 amRNSPrice Monitoring Extension
18th Jun 20207:00 amRNSPDS & Farmacore Announce Co-Development-PDS0204
15th Jun 20202:41 pmRNSPDS Announces Initiation of Phase 2 Trial PDS0101
8th Jun 20204:42 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
5th Jun 20209:14 amRNSPDS Announces Trial of its Lead Product, PDS0101
1st Jun 20207:00 amRNSNotice of AGM
13th May 20202:46 pmRNSPDS Reports Results for Q1 2020 & Business Update
1st May 202011:33 amRNSConfirmation of Board Changes
30th Apr 202012:06 pmRNSPDS expands CRADA with National Cancer Institute
27th Apr 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
17th Apr 20204:40 pmRNSSecond Price Monitoring Extn
17th Apr 20204:36 pmRNSPrice Monitoring Extension
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 20204:40 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20202:02 pmRNSPDS Initiates Programs for COVID-19, PDS0101 delay
14th Apr 20207:04 amRNSPDS Appoints Ilian Iliev to the Board
31st Mar 20207:00 amRNSBoard Changes
30th Mar 20209:39 amRNSHolding(s) in Company
14th Feb 20203:12 pmRNSHolding(s) in Company
12th Feb 202011:07 amRNSPDS equity issue and related party transaction
11th Feb 20202:24 pmRNSPDS Biotechnology proposed offering

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.